BPC-157

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a protective protein found in human gastric juice. It was first characterized by Professor Predrag Sikiric and colleagues at the University of Zagreb in the early 1990s. The peptide does not occur naturally in isolation—it is a specific sequence engineered for research stability and bioavailability.

BPC-157's most distinctive property is its exceptional stability in gastric acid and resistance to enzymatic degradation. This stability allows it to be administered orally in animal models and retain bioactivity—a property almost unique among research peptides. Most peptides are degraded rapidly in the gut, but BPC-157's sequence resists this breakdown, enabling meaningful gastrointestinal research protocols.

The bulk of BPC-157 research has focused on tissue repair (tendon, muscle, ligament, bone), gastrointestinal protection (ulcer models, IBD models, gut-brain axis), wound healing acceleration, and neuroprotection. Secondary areas include cardiovascular protection and organ protection in toxicity models. All published evidence is from animal or in vitro studies—no peer-reviewed human clinical trials have been completed as of 2026.

The most studied mechanisms include: upregulation of growth hormone receptors in fibroblasts (increasing sensitivity to healing signals), activation of the FAK-paxillin pathway (promoting cell adhesion and migration), modulation of the nitric oxide system through Src-Caveolin-1-eNOS phosphorylation (enhancing vascular function), and dual activation of the Egr-1/NAB2 gene loop (promoting organized, non-chaotic blood vessel growth). The peptide does not work through a single receptor but rather through simultaneous modulation of multiple healing pathways.

The Gene Expression Paradox refers to the observation that BPC-157 is cleared from systemic circulation in approximately 15 minutes (mean elimination half-life in rats), yet its reparative effects persist for weeks. Researchers propose that the peptide's brief presence is sufficient to trigger a cascade of gene expression changes—including activation of transcription factors c-Fos, c-Jun, and Egr-1—that initiate self-sustaining healing processes well beyond the peptide's physical presence.

In animal models, yes. BPC-157 retains biological activity when administered orally via gavage in rodent studies, which is attributed to its remarkable stability in gastric juice. This property is well-documented in publications by Sikiric and colleagues. However, whether oral bioavailability translates meaningfully to humans has not been established in clinical trials. Animal gut anatomy and digestive physiology differ from humans, so caution is warranted in extrapolating these findings.

Animal studies have demonstrated BPC-157's cytoprotective effects against NSAID-induced gastric lesions, alcohol-induced stomach damage, stress ulcers, and models of inflammatory bowel disease (ulcerative colitis and Crohn's disease). The peptide appears to reduce mucosal inflammation, accelerate intestinal healing, and restore intestinal barrier function. Its gastric stability makes it particularly suited for GI research, though human clinical evidence is currently absent.

As of early 2026, no peer-reviewed human clinical trials for BPC-157 have been published. The research base—though extensive, comprising over 100 published studies—is entirely preclinical (animal models and in vitro experiments). A Phase I safety study has been mentioned in some literature, but results have not been published. BPC-157 is not approved for human use by any regulatory agency.

In formal pharmacokinetic studies in rats following intravenous administration, BPC-157 has a mean elimination half-life of approximately 15.2 minutes, with the peptide becoming undetectable within 4 hours. This rapid clearance contrasts sharply with its prolonged biological effects, which is the basis of the Gene Expression Paradox. No human pharmacokinetic data has been published.

BPC-157 promotes angiogenesis through the Egr-1/NAB2 regulatory loop, which simultaneously activates vessel growth (Egr-1) and provides an internal brake (NAB2) to prevent disorganized growth. Standard angiogenic factors like VEGF primarily accelerate growth without this built-in regulatory mechanism. Research suggests BPC-157 can promote healing in the eye while opposing pathological vessel growth—a balance that VEGF alone does not provide. This organized approach may be why BPC-157 has been studied in sensitive anatomical areas.

Yes. BPC-157 was added to the World Anti-Doping Agency (WADA) Prohibited List effective January 1, 2022, under category S0 (Non-Approved Substances). This classification prohibits its use by athletes both in and out of competition. WADA's rationale is that BPC-157 is a pharmacological substance not approved for human therapeutic use by any regulatory authority, and its tissue repair properties could provide a performance-enhancing benefit. Athletes subject to USADA, UKAD, or other WADA-signatory testing programs should be aware of this status.

BPC-157 acetate is the original research form — the peptide is paired with an acetate counterion during synthesis. BPC-157 arginine salt pairs the peptide with arginine, which acts as a stabilizing counterion that improves solubility and pH stability in solution. Both forms contain the identical 15-amino acid active peptide sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val). The arginine salt is generally preferred in research for its improved solution stability, particularly at physiological pH ranges.